A Phase 3 interventional study of Glycopyrronium bromide and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Novartis. Completed at 97 sites in 11 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2012-04-12.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 9th largest by enrollment, is one of 4 that started in 2009, is one of 33 in phase 3, and was the 9th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
By country, each count listing its studies:
Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 21 · Phase 3 33 · Phase 4 11
First in 2005; this study’s year is marked. 4 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,324 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 152 across the 73 interventional studies. Of the 67 that completed or were terminated, 49 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 73 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
117 studies in Pulmonary Disease, Chronic Obstructive by Novartis: none open now, none under way, none of them phase 3. Of 110 finished, 94 (85%) have results posted.
Among the 117 studies in Pulmonary Disease, Chronic Obstructive by Novartis, this one is the 10th largest by enrollment of the 116 interventional ones that give a count, is one of 11 that started in 2009, is one of 59 in phase 3, and was the 39th registered.
Novartis’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2003.
1 of the studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 117 in Pulmonary Disease, Chronic Obstructive:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study to assess the safety, tolerability and efficacy of NVA237 versus placebo in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Glycopyrronium bromide 50µg delivered once daily via Single Dose Dry Powder Inhaler (SDDPI). At visit 1 all patients were provided with a short acting β2-agonist (salbutamol/albuterol) which they were instructed to use throughout the study as rescue medication.
Drug: Glycopyrronium bromide
Placebo delivered once daily via SDDPI. At Visit 1 all patients were provided with a short acting β2-agonist (salbutamol/albuterol) which they were instructed to use throughout the study as rescue medication.
Drug: Placebo
Glycopyrronium bromide 50µg was supplied as inhalation capsules for use via a Single Dose Dry Powder Inhaler (SDDPI)
Placebo inhalation capsules were provided for use via a SDDPI
Trough Forced Expiratory Volume in 1 Second (FEV1) at 12 Weeks
Spirometry was conducted according to internationally accepted standards. Trough FEV1 was defined as the average of the 23 hour 15 minute and 23 hour 45 minute post-dose FEV1 readings. Mixed model used baseline FEV1,baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.
Time frame: 12 weeks
Transition Dyspnea Index (TDI) Focal Score After 26 Weeks of Treatment
Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline. Mixed model used baseline TDI, baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.
Time frame: 26 weeks
Quality of Life Assessment With St. George's Respiratory Questionnaire (SGRQ) Total Score After 26 Weeks of Treatment
SGRQ is a health related quality of life questionnaire consisting of 51 items in three components: symptoms, activity, and impacts. The lowest possible value is zero and the highest 100. Higher values correspond to greater impairment in quality of life. Mixed model used baseline SGRQ, baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.
Time frame: 26 weeks
Time to First Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation During 26 Weeks of Treatment
The time to the first moderate or severe COPD exacerbation was the study day on which the patient experienced first moderate or severe COPD exacerbation. COPD exacerbations are considered to be moderate if treatment with systemic corticosteroids and/or antibiotics was required. COPD exacerbations are considered to be severe if treatment for moderate severity and hospitalization were required.
Time frame: 26 weeks
Change From Baseline in the Mean Number of Puffs Per Day of Rescue Medication Over the Study Duration (Baseline to Week 26)
Participants recorded the number of puffs of rescue medication taken in the previous 12 hours in the morning and evening. The total number of puffs of rescue medication per day over the full 26 weeks was calculated and divided by the total number of days with non-missing rescue medication data to derive the mean daily number of puffs of rescue medication taken for the patient.
Time frame: 26 weeks
FEV1 at Each Time-point on Day 1 and Week 26
Spirometry was conducted according to internationally accepted standards. FEV1 was measured at all time points up to 4 hours post-dose, and at 23 hours 15 min and 23 hours 45 min, by visit. Mixed model used baseline FEV1,baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.
Time frame: Day 1 and Week 26
Forced Vital Capacity (FVC) at Each Time-point on Day 1 and Week 26
Spirometry was conducted according to internationally accepted standards. FVC was calculated at each time point up to 4 hours post-dose and at 23 hours 15 min and 23 hours 45 min, by visit. Mixed model used baseline FVC, baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.
Time frame: Day 1 and Week 26
FEV1 Area Under the Curve (AUC) (5 Min - 12 Hour) at Day 1, Week 12 and Week 26
The standardized (with respect to the length of time) area under the curve (AUC) for FEV1 was calculated using trapezoidal rule between 5 min and 12 h post dose at Week 1 Day 1, Week 12 and Week 26 for every patient in the serial spirometry subgroup. Mixed model used baseline FEV1,baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.
Time frame: Day 1, Week 12 and Week 26
FEV1 Area Under Curve (AUC) (5 Min - 23 Hour 45 Min) at Week 12 and Week 26
The standardized (with respect to the length of time) area under the curve (AUC) for FEV1 was calculated using trapezoidal rule between 5 min and 23 h 45 min post dose at week12/week 13and week 26/week 27 where available for every patient in the serial spirometry subgroup. Mixed model used baseline FEV1,baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.
Time frame: Week 12 and Week 26
Trough FEV1 and FVC at Day 1 and Week 26
Spirometry was conducted according to internationally accepted standards. Trough FEV1 was defined as the average of the 23 hour 15 minute and 23 hour 45 minute post-dose FEV1 readings. Mixed model used baseline FEV1, baseline ICS use, FEV1 prior to inhalation of SABA, and FEV1 45 minutes post-inhalation of SABA as covariates. Trough FVC was defined as the average of the 23 hour 15 minute and 23 hour 45 minute post-dose FVC readings. Mixed model used baseline FVC, baseline ICS use, FEV1 prior to inhalation of SABA, and FEV1 45 minutes post-inhalation of SABA as covariates.
Time frame: Day 1 and Week 26
Change in 24-hourly Mean Heart Rate at Day 1, Week 12 and Week 26
The mean heart rate was collected with a 24 hour Holter monitor in a sub-set of the safety population. The change between baseline and day 1, week 12 and week 26 was calculated. The analysis of the Holter recordings was performed by a central facility. Data on heart rate, heart rate variability, supraventricular and ventricular ectopy were collected and assessed.
Time frame: Baseline, Day 1, Week 12 and Week 26
Number of Participants With Adverse Events, Death, and Serious or Clinically Significant Adverse Events or Related Discontinuations
Adverse events are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.
Time frame: 26 Weeks and 30 Day follow-up
Rate of Moderate or Severe COPD Exacerbations Over the 26 Week Treatment Period
One overall rate is calculated for the entire study population. Rate is the number of moderate or severe exacerbations per year = total number of moderate or severe exacerbations for all participants/total number of treatment years for all participants. COPD exacerbations were considered to be moderate if treatment with systemic corticosteroids and/or antibiotics was required. COPD exacerbations were considered to be severe if treatment for moderate severity and hospitalization were required.
Time frame: 26 weeks
Percentage of Nights With no Nighttime Awakenings Over the 26 Week Treatment Period
The percentage of nights with no nighttime awakenings is defined as the total number of nights with no nighttime awakenings over the 26 week treatment period divided by the total number of night where diary recordings have been made. Mixed model used baseline nighttime awakenings, baseline ICS use, FEV1 prior to inhalation of SABA, and FEV1 45 minutes post-inhalation of SABA as covariates.
Time frame: 26 Weeks
Percentage of Days With no Daytime Symptoms Over the 26 Week Treatment Period
The percentage of days with no daytime symptoms is defined as the total number of days with no daytime symptoms over the 26 week treatment period divided by the total number of days where diary recordings have been made. Mixed model used baseline daytime symptoms, baseline ICS use, FEV1 prior to inhalation of SABA, and FEV1 45 minutes post-inhalation of SABA as covariates.
Time frame: 26 Weeks
Percentage of Days Able to Perform Usual Daily Activities Over the 26 Week Treatment Period
The percentage of days able to perform usual daily activities is defined as the total number of days able to perform usual activities over the 26 week treatment period divided by the total number of days where diary recordings have been made. Mixed model used baseline ability to perform usual daily activities, baseline ICS use, FEV1 prior to inhalation of SABA, and FEV1 45 minutes post-inhalation of SABA as covariates.
Time frame: 26 Weeks
Mean Daily Total Symptom Score Over the 26 Week Treatment Period
The daily symptom score was calculated as the sum of the worst of the morning and evening assessments for each symptom (symptoms, cough, wheeze, sputum color/production, and breathlessness). The score can range from 0 to 18 with 0 indicating no symptoms. The higher the score, the worse the symptomatic status. A negative change (lower number) indicates improvement. Mixed model used baseline symptom variables, baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.
Time frame: 26 Weeks
| Milestone | Glycopyrronium Bromide | Placebo |
|---|---|---|
| Started | 552 | 270 |
| Safety population | 550 | 267 |
| Full analysis set | 534 | 260 |
| Completed | 450 | 212 |
| Not completed | 102 | 58 |
| Withdrew: Withdrawal by subject | 38 | 14 |
| Withdrew: Adverse event | 30 | 16 |
| Withdrew: Administrative problems | 21 | 13 |
| Withdrew: Unsatisfactory therapeutic effect | 5 | 5 |
| Withdrew: Protocol violation | 4 | 3 |
| Withdrew: Death | 2 | 3 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Patient's inability to use the device | 1 | 1 |
| Withdrew: No longer requires study drug | 0 | 1 |
Spirometry was conducted according to internationally accepted standards. Trough FEV1 was defined as the average of the 23 hour 15 minute and 23 hour 45 minute post-dose FEV1 readings. Mixed model used baseline FEV1,baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.
| Liters | Glycopyrronium Bromide | Placebo |
|---|---|---|
| Trough Forced Expiratory Volume in 1 Second (FEV1) at 12 Weeks | 1.408 ± 0.0105 | 1.301 ± 0.0137 |
Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline. Mixed model used baseline TDI, baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.
| Units on a scale | Glycopyrronium Bromide | Placebo |
|---|---|---|
| Transition Dyspnea Index (TDI) Focal Score After 26 Weeks of Treatment | 1.84 ± 0.257 | 0.80 ± 0.294 |
SGRQ is a health related quality of life questionnaire consisting of 51 items in three components: symptoms, activity, and impacts. The lowest possible value is zero and the highest 100. Higher values correspond to greater impairment in quality of life. Mixed model used baseline SGRQ, baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.
| Units on a scale | Glycopyrronium Bromide | Placebo |
|---|---|---|
| Quality of Life Assessment With St. George's Respiratory Questionnaire (SGRQ) Total Score After 26 Weeks of Treatment | 39.50 ± 0.813 | 42.31 ± 0.992 |
The time to the first moderate or severe COPD exacerbation was the study day on which the patient experienced first moderate or severe COPD exacerbation. COPD exacerbations are considered to be moderate if treatment with systemic corticosteroids and/or antibiotics was required. COPD exacerbations are considered to be severe if treatment for moderate severity and hospitalization were required.
| Days | Glycopyrronium Bromide | Placebo |
|---|---|---|
| Time to First Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation During 26 Weeks of Treatment | NA (NA to NA) | NA (NA to NA) |
Participants recorded the number of puffs of rescue medication taken in the previous 12 hours in the morning and evening. The total number of puffs of rescue medication per day over the full 26 weeks was calculated and divided by the total number of days with non-missing rescue medication data to derive the mean daily number of puffs of rescue medication taken for the patient.
| Puffs per day | Glycopyrronium Bromide | Placebo |
|---|---|---|
| Change From Baseline in the Mean Number of Puffs Per Day of Rescue Medication Over the Study Duration (Baseline to Week 26) | -1.21 ± 0.122 | -0.75 ± 0.156 |
Spirometry was conducted according to internationally accepted standards. FEV1 was measured at all time points up to 4 hours post-dose, and at 23 hours 15 min and 23 hours 45 min, by visit. Mixed model used baseline FEV1,baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.
| Liters | Glycopyrronium Bromide | Placebo |
|---|---|---|
| Day 1: 5 min (n = 497, 240) | 1.388 ± 0.0057 | 1.295 ± 0.0076 |
| Day 1: 15 min (n = 503, 249) | 1.435 ± 0.0066 | 1.292 ± 0.0087 |
| Day 1: 30 min (n = 511, 252) | 1.472 ± 0.0070 | 1.299 ± 0.0093 |
| Day 1: 1 hour (n = 513, 253) | 1.493 ± 0.0070 | 1.296 ± 0.0094 |
| Day 1: 2 hours (n = 514, 251) | 1.562 ± 0.0076 | 1.355 ± 0.0102 |
| Day 1: 3 hours (n = 519, 248) | 1.544 ± 0.0079 | 1.349 ± 0.0108 |
| Day 1: 4 hours (n = 514, 247) | 1.548 ± 0.0077 | 1.365 ± 0.0105 |
| Day 1: 23 hours 15 min (n = 499, 244) | 1.400 ± 0.0078 | 1.289 ± 0.0103 |
| Day 1: 23 hours 45 min (n = 498, 244) | 1.428 ± 0.0083 | 1.328 ± 0.0108 |
| Week 26: pre-dose trough (n = 447, 208) | 1.371 ± 0.0100 | 1.256 ± 0.0140 |
| Week 26: -45 min (n = 447, 208) | 1.373 ± 0.0104 | 1.256 ± 0.0145 |
| Week 26: -15 min (n = 443, 205) | 1.368 ± 0.0104 | 1.252 ± 0.0144 |
| Week 26: 5 min (n = 439, 208) | 1.409 ± 0.0106 | 1.255 ± 0.0147 |
| Week 26: 15 min (n = 435, 205) | 1.427 ± 0.0109 | 1.269 ± 0.0152 |
| Week 26: 30 min (n = 440, 207) | 1.433 ± 0.0112 | 1.259 ± 0.0155 |
| Week 26: 1 hour (n = 438, 206) | 1.459 ± 0.0115 | 1.251 ± 0.0159 |
| Week 26: 2 hours (n = 438, 203) | 1.508 ± 0.0114 | 1.299 ± 0.0160 |
| Week 26: 3 hours (n = 439, 204) | 1.504 ± 0.0124 | 1.299 ± 0.0170 |
| Week 26: 4 hours (n = 438, 205) | 1.489 ± 0.0114 | 1.312 ± 0.0158 |
| Week 26: 23 hours 15 min (n = 434, 206) | 1.386 ± 0.0118 | 1.267 ± 0.0158 |
| Week 26: 23 hours 45 min (n = 434, 206) | 1.396 ± 0.0116 | 1.282 ± 0.0157 |
Spirometry was conducted according to internationally accepted standards. FVC was calculated at each time point up to 4 hours post-dose and at 23 hours 15 min and 23 hours 45 min, by visit. Mixed model used baseline FVC, baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.
| Liters | Glycopyrronium Bromide | Placebo |
|---|---|---|
| Day 1: 5 min (n = 497, 240) | 2.887 ± 0.0132 | 2.675 ± 0.0173 |
| Day 1: 15 min (n = 503, 249) | 2.943 ± 0.0147 | 2.660 ± 0.0188 |
| Day 1: 30 min (n = 511, 252) | 2.948 ± 0.0155 | 2.637 ± 0.0199 |
| Day 1: 1hour (n = 513, 253) | 3.019 ± 0.0148 | 2.669 ± 0.0198 |
| Day 1: 2 hours (n = 514, 251) | 3.086 ± 0.0166 | 2.754 ± 0.0219 |
| Day 1: 3 hours (n = 519, 248) | 3.096 ± 0.0168 | 2.783 ± 0.0227 |
| Day 1: 4 hours (n = 514, 247) | 3.064 ± 0.0161 | 2.760 ± 0.0217 |
| Day 1: 23 hours 15 min (n = 499, 244) | 2.895 ± 0.0169 | 2.693 ± 0.0221 |
| Day 1: 23 hours 45 min (n = 498, 244) | 2.907 ± 0.0169 | 2.718 ± 0.0219 |
| Week 26: Pre-dose trough (n = 447, 208) | 2.827 ± 0.0238 | 2.623 ± 0.0305 |
| Week 26: -45 min (n = 447, 208) | 2.859 ± 0.0271 | 2.658 ± 0.0337 |
| Week 26: -15 min (n = 443, 205) | 2.798 ± 0.0235 | 2.589 ± 0.0306 |
| Week 26: 5 min (n = 439, 208) | 2.891 ± 0.0251 | 2.639 ± 0.0318 |
| Week 26: 15 min (n = 435, 205) | 2.895 ± 0.0240 | 2.660 ± 0.0309 |
| Week 26: 30 min (n = 440, 207) | 2.885 ± 0.0239 | 2.603 ± 0.0310 |
| Week 26: 1 hour (n = 438, 206) | 2.938 ± 0.0256 | 2.625 ± 0.0329 |
| Week 26: 2 hours (n = 438, 203) | 2.977 ± 0.0225 | 2.687 ± 0.0302 |
| Week 26: 3 hours (n = 439, 204) | 3.016 ± 0.0270 | 2.742 ± 0.0345 |
| Week 26: 4 hours (n = 438, 205) | 2.962 ± 0.0225 | 2.709 ± 0.0303 |
| Week 26: 23 hours 15 min (n = 434, 206) | 2.884 ± 0.0257 | 2.673 ± 0.0322 |
| Week 26: 23 hours 45 min (n = 434, 206) | 2.859 ± 0.0234 | 2.669 ± 0.0306 |
The standardized (with respect to the length of time) area under the curve (AUC) for FEV1 was calculated using trapezoidal rule between 5 min and 12 h post dose at Week 1 Day 1, Week 12 and Week 26 for every patient in the serial spirometry subgroup. Mixed model used baseline FEV1,baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.
| Liters | Glycopyrronium Bromide | Placebo |
|---|---|---|
| Day 1 (n = 169, 83) | 1.475 ± 0.0129 | 1.320 ± 0.0173 |
| Week 12 (n = 153, 75) | 1.433 ± 0.0179 | 1.284 ± 0.0244 |
| Week 26 (n = 149, 70) | 1.445 ± 0.0199 | 1.238 ± 0.0274 |
The standardized (with respect to the length of time) area under the curve (AUC) for FEV1 was calculated using trapezoidal rule between 5 min and 23 h 45 min post dose at week12/week 13and week 26/week 27 where available for every patient in the serial spirometry subgroup. Mixed model used baseline FEV1,baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.
| Liters | Glycopyrronium Bromide | Placebo |
|---|---|---|
| Week 12 (n = 153, 75) | 1.401 ± 0.0167 | 1.268 ± 0.0228 |
| Week 26 (n = 149, 70) | 1.412 ± 0.0185 | 1.213 ± 0.0254 |
Spirometry was conducted according to internationally accepted standards. Trough FEV1 was defined as the average of the 23 hour 15 minute and 23 hour 45 minute post-dose FEV1 readings. Mixed model used baseline FEV1, baseline ICS use, FEV1 prior to inhalation of SABA, and FEV1 45 minutes post-inhalation of SABA as covariates. Trough FVC was defined as the average of the 23 hour 15 minute and 23 hour 45 minute post-dose FVC readings. Mixed model used baseline FVC, baseline ICS use, FEV1 prior to inhalation of SABA, and FEV1 45 minutes post-inhalation of SABA as covariates.
| Liters | Glycopyrronium Bromide | Placebo |
|---|---|---|
| Day 1: FEV1 (n = 508, 248) | 1.414 ± 0.0075 | 1.309 ± 0.0099 |
| Week 26: FEV1 (n = 461, 217) | 1.387 ± 0.0112 | 1.275 ± 0.0150 |
| Day 1: FVC (n = 508, 248) | 2.901 ± 0.0154 | 2.705 ± 0.0202 |
| Week 26: FVC (n = 438, 208) | 2.867 ± 0.0236 | 2.668 ± 0.0300 |
The mean heart rate was collected with a 24 hour Holter monitor in a sub-set of the safety population. The change between baseline and day 1, week 12 and week 26 was calculated. The analysis of the Holter recordings was performed by a central facility. Data on heart rate, heart rate variability, supraventricular and ventricular ectopy were collected and assessed.
| beats per minute | Glycopyrronium Bromide | Placebo |
|---|---|---|
| Day 1: (n = 42, 23) | -1.77 ± 7.583 | -1.28 ± 8.676 |
| Week 12: (n = 42, 20) | -1.99 ± 7.489 | -1.70 ± 7.230 |
| Week 26: (n = 37, 22) | -4.40 ± 9.347 | -2.60 ± 9.349 |
Adverse events are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.
| participants | Glycopyrronium Bromide | Placebo |
|---|---|---|
| Participants with at least one AE | 317 | 174 |
| Death | 3 | 3 |
| SAE(s) | 41 | 24 |
| Discontinuation due to AE(s) | 32 | 19 |
| Discontinuation due to SAE(s) | 15 | 8 |
| Discontinuation due to non-SAE(s) | 18 | 11 |
| AE leading to dose interruption | 12 | 8 |
| AE requiring significant additional therapy | 246 | 155 |
| AE leading to new or prolonged hospitalization | 35 | 21 |
One overall rate is calculated for the entire study population. Rate is the number of moderate or severe exacerbations per year = total number of moderate or severe exacerbations for all participants/total number of treatment years for all participants. COPD exacerbations were considered to be moderate if treatment with systemic corticosteroids and/or antibiotics was required. COPD exacerbations were considered to be severe if treatment for moderate severity and hospitalization were required.
| exacerbations per year | Glycopyrronium Bromide | Placebo |
|---|---|---|
| Rate of Moderate or Severe COPD Exacerbations Over the 26 Week Treatment Period | 0.43 | 0.59 |
The percentage of nights with no nighttime awakenings is defined as the total number of nights with no nighttime awakenings over the 26 week treatment period divided by the total number of night where diary recordings have been made. Mixed model used baseline nighttime awakenings, baseline ICS use, FEV1 prior to inhalation of SABA, and FEV1 45 minutes post-inhalation of SABA as covariates.
| percentage of nights with no awakenings | Glycopyrronium Bromide | Placebo |
|---|---|---|
| Percentage of Nights With no Nighttime Awakenings Over the 26 Week Treatment Period | 55.96 ± 1.537 | 54.37 ± 1.970 |
The percentage of days with no daytime symptoms is defined as the total number of days with no daytime symptoms over the 26 week treatment period divided by the total number of days where diary recordings have been made. Mixed model used baseline daytime symptoms, baseline ICS use, FEV1 prior to inhalation of SABA, and FEV1 45 minutes post-inhalation of SABA as covariates.
| percentage of days with no symptoms | Glycopyrronium Bromide | Placebo |
|---|---|---|
| Percentage of Days With no Daytime Symptoms Over the 26 Week Treatment Period | 5.70 ± 0.799 | 5.78 ± 1.076 |
The percentage of days able to perform usual daily activities is defined as the total number of days able to perform usual activities over the 26 week treatment period divided by the total number of days where diary recordings have been made. Mixed model used baseline ability to perform usual daily activities, baseline ICS use, FEV1 prior to inhalation of SABA, and FEV1 45 minutes post-inhalation of SABA as covariates.
| percentage of days | Glycopyrronium Bromide | Placebo |
|---|---|---|
| Percentage of Days Able to Perform Usual Daily Activities Over the 26 Week Treatment Period | 40.31 ± 1.473 | 35.19 ± 1.907 |
The daily symptom score was calculated as the sum of the worst of the morning and evening assessments for each symptom (symptoms, cough, wheeze, sputum color/production, and breathlessness). The score can range from 0 to 18 with 0 indicating no symptoms. The higher the score, the worse the symptomatic status. A negative change (lower number) indicates improvement. Mixed model used baseline symptom variables, baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.
| units on a scale | Glycopyrronium Bromide | Placebo |
|---|---|---|
| Mean Daily Total Symptom Score Over the 26 Week Treatment Period | -1.54 ± 0.097 | -1.18 ± 0.129 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Glycopyrronium Bromide | — | 41/550 (7.5%) | 132/550 (24%) |
| Placebo | — | 24/267 (9%) | 85/267 (31.8%) |
| Event | Glycopyrronium Bromide | Placebo |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 9/550 | 11/267 |
| Myocardial ischaemiaCardiac disorders | 0/550 | 2/267 |
| PneumoniaInfections and infestations | 4/550 | 2/267 |
| Upper respiratory tract infectionInfections and infestations | 0/550 | 2/267 |
| Upper respiratory tract infection bacterialInfections and infestations | 3/550 | 2/267 |
| Atrial fibrillationCardiac disorders | 3/550 | 0/267 |
| AnaemiaBlood and lymphatic system disorders | 0/550 | 1/267 |
| Cardiac arrestCardiac disorders | 0/550 | 1/267 |
| Myocardial infarctionCardiac disorders | 2/550 | 1/267 |
| Abdominal painGastrointestinal disorders | 0/550 | 1/267 |
| Event | Glycopyrronium Bromide | Placebo |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 105/550 | 67/267 |
| NasopharyngitisInfections and infestations | 28/550 | 21/267 |
| Upper respiratory tract infectionInfections and infestations | 23/550 | 20/267 |
| Age, Customized(participants) | Glycopyrronium Bromide | Placebo | Total |
|---|---|---|---|
| <65 years | 278 | 134 | 412 |
| 65 to <75 years | 199 | 98 | 297 |
| >=75 years | 73 | 35 | 108 |
| Sex: Female, Male(Participants) | Glycopyrronium Bromide | Placebo | Total |
|---|---|---|---|
| Female | 96 | 52 | 148 |
| Male | 454 | 215 | 669 |
The record gives a start of Oct 2009, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2012, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glycopyrrolate
Pulmonary Disease, Chronic Obstructive →